Divide and Conquer

About Divide and Conquer

ConquestBio operates as a drug discovery and development firm, leveraging a sophisticated platform that integrates Artificial Intelligence (AI), Machine Learning (ML), and Generative AI. The company's core strategy involves mining the entire proteomic landscape to identify clinically validated, druggable protein targets for which no small molecule treatments are currently in development. This approach aims to de-risk the initial stages of the drug design and development process. ConquestBio is registered in Delaware and has its operational base in Florida.

The company's primary business is centered on designing and discovering safe and effective small molecule drugs at a large scale. Its technological platform is built to create drugs that inhibit the protein-protein interactions responsible for the pathological progression of serious diseases. The business model appears to be focused on developing a proprietary pipeline of these small molecule drugs. ConquestBio's ambition is to design drugs for over 4,000 targets that have known co-crystal structures, with a goal of producing orally available, safe, and efficacious medications.

The service is built upon a platform that combines structural biology, computational biology, and various forms of artificial intelligence. This allows the company to design drugs with a higher probability of success by focusing on molecular targets that have already been validated through biological and clinical research. By doing so, ConquestBio addresses the high failure rate and costs typically associated with pharmaceutical research and development, offering a more streamlined and targeted approach to creating new therapies. The company's clients would be the patients and healthcare systems that will eventually benefit from these novel, targeted treatments for a range of serious diseases.